Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Carlini MJ, Espinoza-Derout J, Van Alstyne M, Tisdale S, Workman E, Triplett MK, Tattoli I, Yadav S, Henderson CE, Watterson DM, Pellizzoni L. Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy. EMBO Mol Med. 2025 Oct; 17(10):2762-2786.
-
Srour AM, El-Bayaa MN, Temirak A, Alanzy AL, Awad HM, Saleh A, Saleh MG, El-Sayed WA. New benzimidazole-triazole glycoconjugates as anti-cancer agents and EGFR inhibitors. Sci Rep. 2025 Jul 15; 15(1):25514.
-
Nakazawa S, Pecci F, Odintsov I, Gazgalis D, Gottlieb FH, Ricciuti B, Zullo L, Alessi JV, Di Federico A, Aldea M, Garbo E, Gandhi MM, Saini A, Feng WW, Jiang J, Baldacci S, Facchinetti F, Makarem M, Locquet MA, Haratani K, Haradon D, Besse B, Italiano A, Remon J, Lavaud P, Vasseur D, Planchard D, Sato Y, Watanabe Y, Owen S, Cortot AB, Mahran H, Forster MD, Niu J, Tomasini P, Leong SS, Tay K, Esteban E, Minchom A, Kizilbash SH, Cruz-Correa M, Yu KP, Zhang X, Chen P, Sangem M, Che J, Sholl LM, J?nne PA, Awad MM. Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements. Cancer Discov. 2025 Jun 03; 15(6):1129-1140.
-
Dela Cruz MC, Yao X, Roberts N, Iheukwumere P, Carmouche A, Medina PM, Biliran H. TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition. Biochem Biophys Res Commun. 2025 Aug 15; 775:152146.
-
Tran NNQ, Choi H, Sactivel B, Oh YJ, Maeng HJ, Kim MK, Lee J, Kim YB, Lee DH, Oh BC, Jun HS, Chun KH. The dual targeting effects of KD025 on casein kinase 2 and ROCK2 in a mouse model of diet-induced obesity. Biochem Pharmacol. 2025 Jul; 237:116933.
-
Anaya YA, Bracho RP, Chauhan SC, Tripathi MK, Bandyopadhyay D. Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights. Int J Mol Sci. 2025 Mar 16; 26(6).
-
Yang C, Pang X, Teng S, Wilson S, Gu X, Xie G. MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2025 Jan 12; 26(2).
-
Mandala B, Berko Y, Battogtokh G, Fisusi F, Gao H, Akala EO. Nanotechnology Platform for the Delivery of Docetaxel and Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer Therapy. Pharm Nanotechnol. 2025; 13(5):1017-1043.
-
Peng X, Guo S, Zheng S, Hossain A, Zhang C, Mottamal M, Skripnikova E, Ma P, Martinez-Carter K, Zhang Q, Abedin F, Huckaba T, Wang G. Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations. J Med Chem. 2024 Oct 24; 67(20):18098-18123.
-
Dash S, Hanson S, King B, Nyswaner K, Foss K, Tesi N, Harvey MJB, Navarro-Marchal SA, Woods A, Poradosu E, Unciti-Broceta A, Carragher NO, Brognard J. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas. J Biol Chem. 2024 09; 300(9):107615.